Abstract: Described herein is an oral care composition including one or more of the following compounds or compositions: myristic acid, cis-3-hexenylhexanoate, citronellol, nootkatone, ambrette seed absolute, spinach absolute, helichrysum italicum absolute, butanol, geraniol, beta ionone, isoamyl alcohol, methyl (2-pentyl-3-oxocyclopentyl) acetate, anethole, decanoic acid, undecanoic acid, nutmeg oil, clary sage oil, lemongrass oil, lime oil, peppermint oil (for example, mint piperita reco nat, mint piperita boulder sx, or mint piperita yakima single cut), gamma octalactone, 3-hexenyl acetate, lavender oil, cinnamaldehyde, clove oil, mint arvensis oil (for example mint arvensis tpc), linseed oil, and thymol. Also described herein are oral care products incorporating such compositions and related methods.

Abstract: Topical skin compositions and methods for their use are disclosed. The compositions can include at least one skin active ingredient capable of treating a skin condition, and a plurality of skin penetration enhancers capable of increasing the penetration of the skin active into the skin. The plurality of skin penetration enhancers can include alcohol, dimethyl isosorbide, pentylene glycol, ethoxydiglycol, and propylene glycol.

Abstract: Described herein are extracts and compositions of Euterpe oleracea, methods of preparation, and methods of use. The extracts and compositions can be used in various forms of skin care, including as an antioxidant, photoprotector, for soothing skin discomfort, and to reduce or prevent the effects of aging on the skin.

Abstract: A composition comprising at least three probiotic microorganisms, at least three prebiotic compounds, and Polymnia sonchifolia root juice. The probiotic microorganisms are preferably derived from at least Lactococcus lactis, Lactobacillus acidophilus, and Lactobacillus casei. The prebiotic compounds are preferably derived from at least Curcuma longa (turmeric) root extract, Beta vulgaris (beet) root extract, and chicory root extract. The composition may also include lactic acid as a byproduct of fermentation by Lactococcus lactis. The composition may be encapsulated allowing it to adhere to and remain on the skin more effectively and longer than without encapsulation.

Abstract: The present invention relates to a composition comprising at least one probiotic strain of bacteria and at least one postbiotic strain of bacteria. The present invention also relates to a method of improving the appearance skin and/or hair, and a method of altering the microbiome of the skin of a subject, wherein the method comprises orally administering said composition to a subject in need thereof.

Abstract: The present invention relates to biocompatible protein-based particles and their methods of preparation and use. More specifically the present invention relates protein-based particles including protein matrix, spread matrix and/or biocoacervate materials derived from one or more biocompatible purified proteins combined with one or more biocompatible solvents that are used to replace or repair tissue and/or bone in treatments for spinal disc(s), joint(s) (e.g. knee, hip, finger, ankle, elbow, shoulder . . . ) and organ(s) (e.g. bladder, lips, vagina, penis, urethra . . . ). In various embodiments of the present invention the protein-based particles may also include one or more pharmacologically active agents and/or one or more additives.

Abstract: Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.

Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.

Abstract: The present embodiments provide compositions, methods, and kits for the treatment or prevention of ocular conditions or maladies via non-invasive liquid depots. In at least one embodiment, the liquid depot is capable of sustained-release delivery of at least one pharmaceutical agent to the eye for days or weeks.

Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.

Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having at least one coating made at least in part using printing technologies to provide drug storage and drug release structures, notably for hydrophobic drugs and that such hydrophobic drugs can be stabilized as to hydrolysis, heat, and a combination thereof. A first aspect of the present invention includes a packaged medical device that includes at least one drug delivery contact lens. A second aspect of the present invention includes a drug delivery contact lens. A third aspect of the present invention includes a method of making a drug delivery contact lens. A fourth aspect of the present invention includes an ink. A fifth aspect of the present invention includes a method of using a drug delivery contact lens to treat or prevent a disease, disorder, or condition of the eye.

Abstract: The invention relates to dry powder formulations comprising respirable dry particles that contain 1) an antifungal agent in crystalline particulate form, 2) a stabilizer, and 3) one or more excipients.

Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.

Abstract: This document relates to methods and materials for treating cancer. For example, nanostructures (e.g., nanotubes) having one or more anti-cancer agents intercalated in the nanostructures are provided. In some cases, nanostructures (e.g., nanotubes) having one or more anti-cancer agents intercalated in the nanostructures can be administered to a mammal (e.g., a human) having cancer to treat the mammal.

Abstract: The present disclosure relates to a topical transdermal cream and muscle rub formulated to address both skin pain and itch due to inflammation and other problems. The transdermal cream is formulated by components including: cannabidiol (CBD), gamma amino butyric acid (GABA), at least one terpenoid, at least one flavonoid, a penetrant, and at least one emollient. The CBD and GABA components work by perpetrating skin layers and interacting with various receptors in the human body, therefore providing relief. A method of making the topical transdermal cream using the claimed components is also disclosed herein.

Abstract: Suspensions of metronidazole or baclofen and/or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension my include metronidazole or baclofen, and/or a salt or ester derivative thereof a hydrocolloid stabilizer, simethicone emulsion, a buffer, such as sodium citrate, (dihydrate), a preservative, a thickening agent, a sweetener, and water.

Abstract: The present invention relates to a pharmacologically active ingredient-derived molecular association prepared by applying a shear stress to a solution containing a pharmacologically active ingredient.

Abstract: Disclosed herein is a composition comprising: an amount of water; a non-water-soluble substance; and a first excipient, wherein the composition is configured to form a flowable ice slurry when exposed to freezing temperatures. Also disclosed herein is a method of preparing a cold slurry for administration to a patient at a clinical point of care, the method comprising: preparing a composition comprising a plurality of lipid particles; adding an excipient to the composition, wherein the excipient is configured to reduce the freezing point of a volume external to the plurality of lipid particles and of a volume internal to the plurality of lipid particles; and cooling the composition to a predetermined temperature such that the cold slurry is formed, wherein the cold slurry comprises a plurality of ice particles.

Abstract: Described herein are methods for administering a hydrophobic pharmaceutical agent to subjects undergoing extracorporeal membrane oxygenation (ECMO) device therapy while diminishing adsorption of the hydrophobic pharmaceutical agent to the ECMO device. In one embodiment, the method comprises administering the hydrophobic pharmaceutical agent encapsulated in an amphipathic encapsulating agent. In one aspect, the hydrophobic pharmaceutical agent is propofol and the amphipathic encapsulating agent is polyethylene-polypropylene glycol (Poloxamer 407) or a PEGylated liposome. In another aspect, PEGylated propofol is synthesized and used to prevent adsorption to the ECMO device.

Abstract: A submicron structure comprising a silica body defining a plurality of pores that are suitable to receive molecules therein, and having a surface, and a phospholipid bilayer coating the surface, wherein said submicron structure has a maximum dimension of less than one micron, and wherein the phospholipid bilayer stably seals the plurality of pores; and wherein the submicron structure is a member of a monodisperse population of submicron structures.

Abstract: A plurality of particles of tasquinimod in free base form or as a pharmaceutically acceptable salt, said particles having a D(v, 0.9) of at most 30 pm and a D(v, 0.5) of at most 15 ?m. A pharmaceutical composition comprising said particles and preferably one or more pharmaceutically acceptable excipients. A pharmaceutical dosage unit. The particles, composition and dosage unit are useful in the treatment of cancer.

Abstract: Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for cystic fibrosis (CF), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject, wherein the LNPs comprise mRNA encoding a Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein.

Abstract: The present invention relates to new solid forms (NSF) of a flavonoid and a coformer. The NSF are co-amorphous solids of flavonoids and amino acids, as well as the solvates of said co-amorphous solids. The flavonoid is selected from quercetin, genistein, fisetin, apigenin, naringenin, rutin, diosmin, among others. The coformer is selected from lysine and arginine. The NSF have enhanced stability, solubility and pharmacological properties over parent polyphenols. The new solid forms are suitable to be used in pharmaceutical compositions, food products, nutritional supplements and the like.

Abstract: A printed composition for biomedical uses comprises a liquid droplet prior to crosslinking and a gelled particle after crosslinking, where the liquid droplet comprises a formulation including a hydrogel precursor and abiologic, and the gelled particle comprises a cross-linked hydrogel matrix with the biologic dispersed therein. The formulation has a viscosity in a range from about 100 mPa-s to about 500,000 mPa-s.

Abstract: Formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.

Abstract: Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.

Abstract: The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising wax coated tablets. Specifically, a wax coating can be applied to a pharmaceutical tablet prior to the film coating process.

Abstract: Therapeutic index (TI) is a measure of drug safety based on the differential between minimal effective dose and maximal tolerable dose. Many small-molecule drugs show limited TI (below 10). Given patient variability, such a limited range can become further narrowed for a drug in practice, complicating its real-world use. Epigenetic drugs such as nuclear receptor ligands (NRLs)—which must reach the target cell's nucleus in order to function—pose a particular challenge because small-molecule drugs typically lack the evolved biological “intelligence” that natural molecules employ in order to reach their intracellular targets efficiently. Methods and compositions are disclosed herein for the treatment of peripheral immune tissues (PIT) using NRLs covalently attached to immodulin peptides. PIT includes surface draining lymph nodes of the upper and lower limbs and adjacent skin tissues.

Abstract: Compositions and methods for increasing the solubility and stability of organic nucleotide materials via microencapsulation techniques. A method for making a shelf-stable organic nucleotide compound in a more water-soluble form, the higher-solubility form being provided in liquid and/or powder. The method utilizes a colloidal dispersion solution comprising water, polysaccharides, organic nucleotide and in some cases surfactants. A method for making shelf-stable composition comprising at least one organic nucleotide composition may include combining water, surfactant, polysaccharide, and ATP to form an intermixed colloidal dispersion. The method may include heating the admixed dispersion and running the dispersion under medium shear, wherein the colloidal dispersion provides improved shelf stability to the target nucleotide in water-soluble form.

Abstract: A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials is provided. The method includes the sequential steps of (a) loading the particles comprising the drug into a reactor, (b) applying a vaporous or gaseous metal precursor to the particles in the reactor, (c) performing one or more pump-purge cycles of the reactor using inert gas, (d) applying a vaporous or gaseous oxidant to the particles in the reactor, and (e) performing one or more pump-purge cycles of the reactor using inert gas. The temperature of the particles does not exceed 35° C. This produces a pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials.

Abstract: Described herein are methods of treating cancer by administering to a subject a composition comprising ultrasmall silica nanoparticles to enhance one or more of the following immunotherapies: chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint blockade antibody therapy (ICB), immune inhibitor therapy (e.g., myeloid-targeting inhibitors). In some embodiments, the compositions are used in combination with external beam radiotherapy.

Abstract: The present disclosure provides a lipid nanoparticle for extrahepatic delivery of mRNA, the lipid nanoparticle comprising: (i) mRNA cargo; (ii) a phosphatidylcholine lipid content of from 30 mol % to 70 mol %; (iii) a ionizable, cationic lipid content of from 5 mol % to 50 mol %; (iv) a sterol selected from cholesterol or a derivative thereof; and (v) a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0.5 mol % to 5 mol. Further provided is a lipid nanoparticle comprising encapsulated mRNA and 20 to 70 mol % of a phosphatidylcholine lipid, an ionizable lipid; and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticle exhibiting at least a 10% increase in gene expression of the mRNA in vivo as measured in one or more extrahepatic organs or tissues. Further provided are methods of administration of such lipid nanoparticles.

Abstract: An inhalable nanocrystal-based suspension formulation of nintedanib (NTB) (NTB-NS) possessing specific physicochemical properties to enhance drug retention in the lung was developed for localized treatment of pulmonary fibrosis via inhalation. This NTB-NS formulation was prepared using a wet-milling procedure in the presence of a surfactant, PLURONIC® F127, to endow the formulation with non-adhesive surface coatings to minimize interactions with therapy-inactivating delivery barriers in the lung.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of agomelatine comprising a self-adhesive layer structure containing a therapeutically effective amount of agomelatine, such agomelatine TTS for use in a method of treatment, a method of treatment comprising applying such agomelatine TTS, and processes of manufacture of such TTS.

Abstract: In one embodiment, the object of the present invention is to provide a nephrotoxicity reducing agent for a pharmaceutical composition comprising an antisense oligomer, and a method for reducing nephrotoxicity of the pharmaceutical composition. In one embodiment, the present invention relates to a nephrotoxicity reducing agent for a pharmaceutical composition comprising an antisense oligomer, wherein the nephrotoxicity reducing agent comprises a sugar alcohol and is used in an amount such that the concentration of the sugar alcohol in the pharmaceutical composition is 1 mg/ml to 400 mg/mL.

Abstract: This invention provides a novel preventive and/or therapeutic agent for vascular cognitive impairment, comprising, as an active ingredient, a compound that has not previously been demonstrated to have a preventive and/or therapeutic effect on vascular cognitive impairment in humans. The invention provides a preventive and/or therapeutic agent for vascular cognitive impairment in humans, comprising a polyphenol compound.

Abstract: The present invention provides Cannabis oil compositions, including Cannabis oil compositions containing vitamin E, and methods for preparing the Cannabis oil compositions. In some embodiments, the invention provides a method for preparing a Cannabis oil composition comprising eluting cannabinoids from Cannabis plant material with a solvent to produce an eluate; filtering the eluate with a filter to produce a filtrate; evaporating the solvent from the filtrate with a distiller to produce a distillate; and purging the distillate under conditions sufficient to remove residual solvent. In some embodiments, the method further includes mixing a quantity of vitamin E with the extract. Blended Cannabis oil compositions containing mixtures of Cannabis oil preparations are also described.

Abstract: The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

Abstract: The present invention provides a small molecule TNF-? inhibitor STU104 and a preparation method and use thereof, wherein an absolute configuration of an optical isomer (R)-STU104 is identified, especially it has found use of STU104 for treatment of autoimmune inflammatory diseases mediated due to TNF-? overexpression including ulcerative colitis, Crohn's disease, rheumatoid arthritis, osteoarthritis, alopecia areata, Sjogren's syndrome, lupus erythematosus, dermatomyositis, etc. The present invention has broad clinical therapeutic significance.

Abstract: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed are methods to stimulate intracellular mitophagy in a cell nucleus of a subject in need thereof, by administering to the subject an effective amount of a sterol regulatory element-binding protein (SREBP) signaling pathway activator that induces nuclear translocation of SREBP C-terminal regulatory domain into the cell nucleus.

Abstract: A composition for treating an oral cavity in a patient in need is provided. The composition comprising a medicament, a polyvinyl alcohol (PVA), and optionally a humectant, the medicament in an amount of about 0.001% w/w, v/v or w/v to about 5% w/w, v/v or w/v, the polyvinyl alcohol in an amount of about 5% w/w, v/v or w/v to about 99% w/w, v/v or w/v, the humectant in an amount of about 0.5% w/w, v/v or w/v to about 15% w/w, v/v or w/v based on a total w/w, v/v or w/v of the composition. A method of making a composition for treating an oral cavity in a patient in need is also provided.

Abstract: In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, APIS1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, APIS1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.

Abstract: In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.

Abstract: The present invention relates to a therapeutic agent of a lipase inhibitor for a wide spectrum of RNA viral infections in humans and animals. More specifically, the lipase inhibitor can be used as a therapeutic agent for influenza A virus infection, bovine coronavirus infection, porcine epidemic diarrhea coronavirus infection, bovine rotavirus infection, porcine reproductive and respiratory syndrome virus infection, and sapoviral infection and furthermore, can be utilized as a therapeutic agent for various RNA viral infections in humans and animals, such as infections with SARS COV-1, MERS-COV, Zika virus, dengue fever virus, and hepatitis A and C viruses.

Abstract: The invention involves a novel method of terminating arrhythmic storm in patients following implementation of an implantable defibrillator by administrating loading and maintenance infusions of dofetilide intravenously followed by oral dosing.

Abstract: The invention involves a novel method of converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL by administering at least a loading dose of dofetilide intravenously, or if that fails cardioversion and a maintenance infusion followed by a switch to chronic oral dosing.

Abstract: Provided herein are methods of administering GHB formulations for the treatment of narcolepsy and other conditions.

Abstract: Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or anaolg thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.